Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05981092 · ClinicalTrials.gov registry record
A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)
A clinical trial of Cardiomyopathy, Dilated and Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM), sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- 35
- Enrollment target
- 15
- Study locations
NCT05981092: Active study of Cardiomyopathy, Dilated and Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM), sponsored by Alexion Pharmaceuticals.
NCT05981092 is a study of Cardiomyopathy, Dilated and Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM) that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 35 participants. The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05981092, a study of Cardiomyopathy, Dilated and Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM), is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 35 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to learn about the natural progression of DCM (dilated cardiomyopathy) caused by BAG3 gene mutations. DCM is a condition as the heart muscle is weakened and the heart becomes enlarged. This makes it hard for the heart to pump enough blood for the body. The study is seeking up to about 35 participants who have: * BAG3 mutation (change in the gene) that causes or is likely to cause dilated cardiomyopathy * NYHA (New York Heart Association) Class I-IV at screening (Stage B-D) * Left Ventricular Ejection Fraction less than or equal to 50% (meaning reduced heart function) All participants in this study will receive their usual treatment. The investigators will observe the natural progression of people who have BAG3 DCM. This will help the investigators better understand the disease and aid in future research. Participants will take part in this study for three years. During this time, participants will visit the site at least 8 times (about every 3 months for the first year and annually during year 2 and three). Participants will undergo study procedures and give information about their health. These procedures will include a physical exam, cardiac magnetic resonance imaging, echocardiography, ECG monitoring, activity monitoring, cardiopulmonary exercise testing, and blood tests. Participants will answer questions about health and quality of life. The study team will also call participants about 1 time over the phone.
Primary Outcome
Baseline measures of left ventricular volumes at end systole and diastole using imaging at baseline.
Conditions Studied
Study Locations (15)
Other
- Research Site - Amsterdam
- Research Site - Maastricht
- Research Site - Warsaw
- Research Site - A Coruña
- Research Site - Madrid
- Research Site - London
California
- Research Site - Palo Alto
Colorado
- Research Site - Aurora
Massachusetts
- Research Site - Boston
Minnesota
- Research Site - Rochester
New York
- Research Site - The Bronx
Pennsylvania
- Research Site - Philadelphia
Madrid
- Research Site - Majadahonda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2027-08-12 |
What the registry record for NCT05981092 still lists
NCT05981092 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 2 conditions, with Cardiomyopathy, Dilated appearing as the primary indexed condition, and to 0 interventions.
NCT05981092 lists 15 locations in 10 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT05981092 about?
NCT05981092 is a clinical study titled "A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)". The purpose of this study is to learn about the natural progression of DCM (dilated cardiomyopathy) caused by BAG3 gene mutations. DCM is a condition as the heart muscle is weakened and the heart becomes enlarged. This makes it hard for the heart to pump enough blood for the body. The study is seek...
What is the current status of trial NCT05981092?
This trial is currently active not recruiting. The enrollment target is 35 participants. The study started on 2022-10-14. Estimated completion is 2027-08-12.
What conditions does trial NCT05981092 study?
This clinical trial studies the following conditions: Cardiomyopathy, Dilated, Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM).
Who is sponsoring clinical trial NCT05981092?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05981092 being conducted?
This trial has 15 study locations across California, Colorado, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiomyopathy, Dilated
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI